IL-12-expressing exosome CDK-003

{
  "id": "MLC-T-ONC-014346",
  "term": "IL-12-expressing exosome CDK-003",
  "field": "Oncology and biomedicine",
  "definition": "Exosome engineered to display the human pro-inflammatory cytokine interleukin-12 (IL-12) in a fully active form on the surface via the exosome surface glycoprotein prostaglandin F2 receptor negative regulator (PTGFRN; CD315), with potential immunostimulating and antineoplastic activities. Upon intralesional administration of IL-12-expressing exosome CDK-003, IL-12 expressed by the exosome may activate the immune system in the tumor microenvironment (TME) by promoting the activation of natural killer (NK) cells, inducing secretion of interferon-gamma (IFN-g) and inducing cytotoxic T-lymphocyte (CTL) responses against tumor cells. This may result in immune-mediated tumor cell death, inhibition of tumor cell proliferation and inhibition of tumor angiogenesis. The exosome-based formulation may provide targeted anti-tumor immunity while minimizing off-target toxicity. PTGFRN, expressed on the surface of the exosome, enables the engagement of the IL-12 receptor (IL-12R) on immune effector cells such as T cells and NK cells.",
  "synonyms": [
    "IL-12-displaying therapeutic exosome CDK-003",
    "IL-12/PTGFRN-expressing exosome CDK-003"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/il-12-expressing-exosome-cdk-003/"
}